FdaApplication
BLA 761152
Identifiers
- fda_app_no: BLA761152
Properties
| Property | Value |
|---|---|
| applicant_name | Omeros Corporation |
| application_type | BLA |
| approval_date | 2025-12-23 |
Revenue by product
YARTEMLEA
| Period | Revenue |
|---|---|
| Q1 2026 | $9.9M† |
| Q1 2025 | $0.0M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| YARTEMLEA | NARSOPLIMAB-WUUG | 370MG/2ML | Injection |
1 product